Comparative Pharmacology
Head-to-head clinical analysis: BRIVARACETAM versus PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVARACETAM versus PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE.
BRIVARACETAM vs PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Phentermine is a sympathomimetic amine that stimulates norepinephrine release in the hypothalamus, reducing appetite. Topiramate modulates GABA-A receptors, inhibits AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase, enhancing satiety and reducing cravings.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
Oral: Initial 3.75 mg phentermine / 23 mg topiramate once daily for 14 days, then increase to 7.5 mg/46 mg once daily. If <3% weight loss after 12 weeks, discontinue or escalate to 15 mg/92 mg once daily.
None Documented
None Documented
Clinical Note
moderateBrivaracetam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Fluconazole
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
Phentermine: 20-25 hours (terminal); Topiramate: 19-23 hours (healthy adults), prolonged in renal impairment (up to 35 hours). Clinical context: Steady state reached in 4-5 days; supports once-daily dosing.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
Phentermine: Renal (80% unchanged, 20% as metabolites). Topiramate: Renal (70% unchanged, 30% metabolized). Total dose eliminated renally: >90% combined.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Brivaracetam."